Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases

Nathalie Rioux-Leclercq, Patricia Fergelot, Salim Zerrouki, Emmanuelle Leray, Florence Jouan, Pascale Bellaud, Jonathan Ira Epstein, Jean Jacques Patard

Research output: Contribution to journalArticle

Abstract

Vascular endothelial growth factor (VEGF) is the major factor involved in angiogenesis. Although it is known that one of the functions of VEGF is to regulate neovascularization in renal cell carcinomas, the relationship between the production of VEGF in tumor tissue and its concentration in blood has not yet been studied. The aims of this study were to determine, in a series of conventional renal cell carcinoma (CRCC) cases, (1) VEGF expression and VEGF pattern in tumor cells, (2) the relationship between VEGF expression/pattern and VEGF levels in plasma (pVEGF), and (3) the association with usual clinical and pathologic prognostic factors. Fifty patients operated on for CRCC by radical nephrectomy were included. Clinical and histologic parameters were studied. VEGF expression and VEGF pattern in tumor cells was immunohistochemically recorded. pVEGF levels and platelet count were analyzed in relation to clinical and histologic parameters. Intratumoral VEGF expression associated with a cytoplasmic VEGF pattern was significantly higher in patients with high pVEGF levels (P = .01). Both VEGF expression and pVEGF levels were significantly correlated with Fuhrman grade (P = .002 and P = .01, respectively) and tumor stage (P = .006 and P = .008, respectively). In addition, VEGF expression was also correlated with tumor necrosis (P = .001) and progression (P = .001). We demonstrated that in CRCC with tumor necrosis, VEGF expression, pVEGF levels, and platelet count were significantly higher than in CRCC with no tumor necrosis (P = .001, P = .03, and P = .001, respectively). Our results revealed that cytoplasmic VEGF expression and pVEGF levels are associated with usual prognostic factors and progression in CRCC, which may allow VEGF to be used as a prognostic marker for CRCC, especially in patients with VEGF-targeted therapy.

Original languageEnglish (US)
Pages (from-to)1489-1495
Number of pages7
JournalHuman Pathology
Volume38
Issue number10
DOIs
StatePublished - Oct 2007

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
Prospective Studies
Neoplasms
Necrosis
Platelet Count
Nephrectomy

Keywords

  • Immunohistochemistry
  • Necrosis
  • Platelets
  • Prognostic factors
  • RCC, renal cell carcinoma
  • VEGF, vascular endothelial growth factor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Rioux-Leclercq, N., Fergelot, P., Zerrouki, S., Leray, E., Jouan, F., Bellaud, P., ... Patard, J. J. (2007). Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Human Pathology, 38(10), 1489-1495. https://doi.org/10.1016/j.humpath.2007.02.014

Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma : a prospective study of 50 cases. / Rioux-Leclercq, Nathalie; Fergelot, Patricia; Zerrouki, Salim; Leray, Emmanuelle; Jouan, Florence; Bellaud, Pascale; Epstein, Jonathan Ira; Patard, Jean Jacques.

In: Human Pathology, Vol. 38, No. 10, 10.2007, p. 1489-1495.

Research output: Contribution to journalArticle

Rioux-Leclercq, Nathalie ; Fergelot, Patricia ; Zerrouki, Salim ; Leray, Emmanuelle ; Jouan, Florence ; Bellaud, Pascale ; Epstein, Jonathan Ira ; Patard, Jean Jacques. / Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma : a prospective study of 50 cases. In: Human Pathology. 2007 ; Vol. 38, No. 10. pp. 1489-1495.
@article{75dce5a7ee8649caa24f68def86f82ec,
title = "Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases",
abstract = "Vascular endothelial growth factor (VEGF) is the major factor involved in angiogenesis. Although it is known that one of the functions of VEGF is to regulate neovascularization in renal cell carcinomas, the relationship between the production of VEGF in tumor tissue and its concentration in blood has not yet been studied. The aims of this study were to determine, in a series of conventional renal cell carcinoma (CRCC) cases, (1) VEGF expression and VEGF pattern in tumor cells, (2) the relationship between VEGF expression/pattern and VEGF levels in plasma (pVEGF), and (3) the association with usual clinical and pathologic prognostic factors. Fifty patients operated on for CRCC by radical nephrectomy were included. Clinical and histologic parameters were studied. VEGF expression and VEGF pattern in tumor cells was immunohistochemically recorded. pVEGF levels and platelet count were analyzed in relation to clinical and histologic parameters. Intratumoral VEGF expression associated with a cytoplasmic VEGF pattern was significantly higher in patients with high pVEGF levels (P = .01). Both VEGF expression and pVEGF levels were significantly correlated with Fuhrman grade (P = .002 and P = .01, respectively) and tumor stage (P = .006 and P = .008, respectively). In addition, VEGF expression was also correlated with tumor necrosis (P = .001) and progression (P = .001). We demonstrated that in CRCC with tumor necrosis, VEGF expression, pVEGF levels, and platelet count were significantly higher than in CRCC with no tumor necrosis (P = .001, P = .03, and P = .001, respectively). Our results revealed that cytoplasmic VEGF expression and pVEGF levels are associated with usual prognostic factors and progression in CRCC, which may allow VEGF to be used as a prognostic marker for CRCC, especially in patients with VEGF-targeted therapy.",
keywords = "Immunohistochemistry, Necrosis, Platelets, Prognostic factors, RCC, renal cell carcinoma, VEGF, vascular endothelial growth factor",
author = "Nathalie Rioux-Leclercq and Patricia Fergelot and Salim Zerrouki and Emmanuelle Leray and Florence Jouan and Pascale Bellaud and Epstein, {Jonathan Ira} and Patard, {Jean Jacques}",
year = "2007",
month = "10",
doi = "10.1016/j.humpath.2007.02.014",
language = "English (US)",
volume = "38",
pages = "1489--1495",
journal = "Human Pathology",
issn = "0046-8177",
publisher = "W.B. Saunders Ltd",
number = "10",

}

TY - JOUR

T1 - Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma

T2 - a prospective study of 50 cases

AU - Rioux-Leclercq, Nathalie

AU - Fergelot, Patricia

AU - Zerrouki, Salim

AU - Leray, Emmanuelle

AU - Jouan, Florence

AU - Bellaud, Pascale

AU - Epstein, Jonathan Ira

AU - Patard, Jean Jacques

PY - 2007/10

Y1 - 2007/10

N2 - Vascular endothelial growth factor (VEGF) is the major factor involved in angiogenesis. Although it is known that one of the functions of VEGF is to regulate neovascularization in renal cell carcinomas, the relationship between the production of VEGF in tumor tissue and its concentration in blood has not yet been studied. The aims of this study were to determine, in a series of conventional renal cell carcinoma (CRCC) cases, (1) VEGF expression and VEGF pattern in tumor cells, (2) the relationship between VEGF expression/pattern and VEGF levels in plasma (pVEGF), and (3) the association with usual clinical and pathologic prognostic factors. Fifty patients operated on for CRCC by radical nephrectomy were included. Clinical and histologic parameters were studied. VEGF expression and VEGF pattern in tumor cells was immunohistochemically recorded. pVEGF levels and platelet count were analyzed in relation to clinical and histologic parameters. Intratumoral VEGF expression associated with a cytoplasmic VEGF pattern was significantly higher in patients with high pVEGF levels (P = .01). Both VEGF expression and pVEGF levels were significantly correlated with Fuhrman grade (P = .002 and P = .01, respectively) and tumor stage (P = .006 and P = .008, respectively). In addition, VEGF expression was also correlated with tumor necrosis (P = .001) and progression (P = .001). We demonstrated that in CRCC with tumor necrosis, VEGF expression, pVEGF levels, and platelet count were significantly higher than in CRCC with no tumor necrosis (P = .001, P = .03, and P = .001, respectively). Our results revealed that cytoplasmic VEGF expression and pVEGF levels are associated with usual prognostic factors and progression in CRCC, which may allow VEGF to be used as a prognostic marker for CRCC, especially in patients with VEGF-targeted therapy.

AB - Vascular endothelial growth factor (VEGF) is the major factor involved in angiogenesis. Although it is known that one of the functions of VEGF is to regulate neovascularization in renal cell carcinomas, the relationship between the production of VEGF in tumor tissue and its concentration in blood has not yet been studied. The aims of this study were to determine, in a series of conventional renal cell carcinoma (CRCC) cases, (1) VEGF expression and VEGF pattern in tumor cells, (2) the relationship between VEGF expression/pattern and VEGF levels in plasma (pVEGF), and (3) the association with usual clinical and pathologic prognostic factors. Fifty patients operated on for CRCC by radical nephrectomy were included. Clinical and histologic parameters were studied. VEGF expression and VEGF pattern in tumor cells was immunohistochemically recorded. pVEGF levels and platelet count were analyzed in relation to clinical and histologic parameters. Intratumoral VEGF expression associated with a cytoplasmic VEGF pattern was significantly higher in patients with high pVEGF levels (P = .01). Both VEGF expression and pVEGF levels were significantly correlated with Fuhrman grade (P = .002 and P = .01, respectively) and tumor stage (P = .006 and P = .008, respectively). In addition, VEGF expression was also correlated with tumor necrosis (P = .001) and progression (P = .001). We demonstrated that in CRCC with tumor necrosis, VEGF expression, pVEGF levels, and platelet count were significantly higher than in CRCC with no tumor necrosis (P = .001, P = .03, and P = .001, respectively). Our results revealed that cytoplasmic VEGF expression and pVEGF levels are associated with usual prognostic factors and progression in CRCC, which may allow VEGF to be used as a prognostic marker for CRCC, especially in patients with VEGF-targeted therapy.

KW - Immunohistochemistry

KW - Necrosis

KW - Platelets

KW - Prognostic factors

KW - RCC, renal cell carcinoma

KW - VEGF, vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=34548680964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548680964&partnerID=8YFLogxK

U2 - 10.1016/j.humpath.2007.02.014

DO - 10.1016/j.humpath.2007.02.014

M3 - Article

C2 - 17597181

AN - SCOPUS:34548680964

VL - 38

SP - 1489

EP - 1495

JO - Human Pathology

JF - Human Pathology

SN - 0046-8177

IS - 10

ER -